7,845 Shares in BridgeBio Pharma, Inc. $BBIO Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. bought a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 7,845 shares of the company’s stock, valued at approximately $407,000.

Other hedge funds have also made changes to their positions in the company. Norges Bank acquired a new stake in shares of BridgeBio Pharma during the second quarter worth approximately $84,488,000. Invesco Ltd. boosted its stake in shares of BridgeBio Pharma by 27.0% during the 2nd quarter. Invesco Ltd. now owns 2,801,065 shares of the company’s stock valued at $120,950,000 after buying an additional 594,902 shares during the period. Franklin Resources Inc. grew its holdings in shares of BridgeBio Pharma by 142.1% during the 2nd quarter. Franklin Resources Inc. now owns 821,405 shares of the company’s stock valued at $35,468,000 after acquiring an additional 482,149 shares in the last quarter. Gilder Gagnon Howe & Co. LLC increased its stake in shares of BridgeBio Pharma by 280.7% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 465,401 shares of the company’s stock worth $20,096,000 after acquiring an additional 343,158 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new stake in shares of BridgeBio Pharma during the second quarter worth $11,986,000. 99.85% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Thomas Trimarchi sold 13,600 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total value of $1,016,192.00. Following the sale, the chief financial officer directly owned 336,585 shares of the company’s stock, valued at approximately $25,149,631.20. This trade represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $71.94, for a total value of $2,877,600.00. Following the completion of the transaction, the chief executive officer owned 695,686 shares in the company, valued at $50,047,650.84. The trade was a 5.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 176,121 shares of company stock valued at $13,009,631 in the last quarter. 18.20% of the stock is currently owned by corporate insiders.

BridgeBio Pharma Stock Down 2.5%

Shares of BridgeBio Pharma stock opened at $73.93 on Thursday. BridgeBio Pharma, Inc. has a 12-month low of $28.33 and a 12-month high of $84.94. The stock has a 50 day moving average price of $75.73 and a two-hundred day moving average price of $63.79. The stock has a market capitalization of $14.25 billion, a P/E ratio of -17.69 and a beta of 1.13.

Analyst Upgrades and Downgrades

A number of research analysts have commented on BBIO shares. Piper Sandler boosted their target price on BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Wednesday, January 21st. Wells Fargo & Company raised their price objective on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the company an “overweight” rating in a research report on Friday, February 13th. Cantor Fitzgerald boosted their target price on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. Finally, Evercore restated an “outperform” rating on shares of BridgeBio Pharma in a research note on Monday, October 27th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $82.05.

Key BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target to $100 and reiterated a Buy rating, signaling bullish analyst support that could underpin the stock. Benzinga
• Positive Sentiment: Several Wall Street firms maintain buy/overweight ratings and a median 6‑month target near $94, providing analyst-driven upside thesis for investors focused on BBIO’s pipeline and long-term growth. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results after the close on Feb. 24 and host a 4:30 pm ET conference call — an event that can create short‑term volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to 34 new employees (76,701 aggregate shares) under Nasdaq rules; vesting schedules could modestly increase share-based compensation and future float. Inducement Grants
• Negative Sentiment: Multiple senior insiders sold stock on Feb. 17: Director Randal W. Scott (10,000 shares). These disclosed Form 4s reduce insider ownership and can spook investors when clustered. Scott Form 4
• Negative Sentiment: CFO Thomas Trimarchi sold 13,600 shares (≈$1.02M) and CAO Maricel Apuli sold 510 shares; clustered executive selling raises near‑term governance/ownership concerns for some investors. Trimarchi Form 4 Apuli Form 4
• Negative Sentiment: Data providers note a long history of insider sales (many officers have sold substantial blocks over recent months), which can weigh on sentiment even as analysts remain constructive. Insider/Analyst Summary

BridgeBio Pharma Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.